Background & Aims In low-income countries, point-of-care photometers are used in the screening and management of anaemia in individuals, but also in the assessment of population iron status when evaluating efficacy of intervention studies or public health interventions. We aimed to evaluate the accuracy of a commonly used photometer, HemoCue-301, in determining haemoglobin concentration among anaemic children aged 6-12 months in a field setting in rural Africa.
{"title":"Comparison of haemoglobin concentration measurements using HemoCue-301 and Sysmex XN-Series 1500: a survey among anaemic Gambian infants aged 6-12 months","authors":"Mamadou Bah, Hans Verhoef, Abdou Camara, Morris Nden Ngom, Demba Jallow, Kebba Bajo, Foday Bah, Maarten Pleij, Maaike Klappe, Alasana Saidykhan, Emmanuel Okoh, Abdoulie Bah, Carla Cerami","doi":"10.1101/2024.09.05.24313093","DOIUrl":"https://doi.org/10.1101/2024.09.05.24313093","url":null,"abstract":"<strong>Background & Aims</strong> In low-income countries, point-of-care photometers are used in the screening and management of anaemia in individuals, but also in the assessment of population iron status when evaluating efficacy of intervention studies or public health interventions. We aimed to evaluate the accuracy of a commonly used photometer, HemoCue-301, in determining haemoglobin concentration among anaemic children aged 6-12 months in a field setting in rural Africa.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-04DOI: 10.1101/2024.09.03.24312976
Satarupta Basu, Soma Gupta, Rajib De, Shuvra Neel Baul, Aditi Sen, Shreyashi Dasgupta, Arindam Biswas
Background and Objectives Microcytic hypochromic anemia is the most common feature of alpha-thalassemia and depends on the number of alpha genes deleted. Therefore, in this study, we aim to determine the most common deletion mutations among microcytic anemia cases of West Bengal and correlate them with different biochemical parameters and endophenotypes.
{"title":"Detection of Common Deletion Mutations (− α3.7 and − α4.2 kb) in HBA gene and Genotype-Phenotype Correlation","authors":"Satarupta Basu, Soma Gupta, Rajib De, Shuvra Neel Baul, Aditi Sen, Shreyashi Dasgupta, Arindam Biswas","doi":"10.1101/2024.09.03.24312976","DOIUrl":"https://doi.org/10.1101/2024.09.03.24312976","url":null,"abstract":"<strong>Background and Objectives</strong> Microcytic hypochromic anemia is the most common feature of alpha-thalassemia and depends on the number of alpha genes deleted. Therefore, in this study, we aim to determine the most common deletion mutations among microcytic anemia cases of West Bengal and correlate them with different biochemical parameters and endophenotypes.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-27DOI: 10.1101/2024.08.23.24312359
Dimitrios Tsallos, Nemo K. Ikonen, Juho J. Miettinen, Muntasir M. Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O'Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Caroline A. Heckman
Despite development of several effective therapies for multiple myeloma (MM), the prognosis of patients with partial deletion of chromosome 17 (del(17p)) and TP53 aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and transcriptome sequencing plus proteomics) and functional ex vivo drug screening to samples from 167 patients with MM, we uncovered novel therapeutic vulnerabilities specific to TP53 mutated MM. Our findings revealed a distinct sensitivity profile to a range of inhibitors (mitotic, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR inhibitors) irrespective of 17p deletion status. Conversely, no increase in sensitivity was observed for monoallelic TP53 (del(17p) with WT TP53) when compared to WT TP53 samples, highlighting the remaining unmet clinical need. Notably, plicamycin, an RNA synthesis inhibitor linked to modulation of chromatin structure and increased transcription, emerged as particularly efficacious for TP53 mutated MM. The increased sensitivity correlated with higher protein expression of the drug targets: HDAC2, HSP90AA1 and multiple ribosomal subunits. Additionally, we observed increased RNA expression of G2M checkpoint, E2F targets and mTORC1 signaling in our cohort and the MMRF-CoMMpass (NCT01454297) study in TP53 mutated MM. Harmonization of multi-omics data with ex vivo drug screening results revealed that TP53 mutated MM is functionally distinct from MM with monoallelic TP53, and demonstrate that MM with mutated TP53, with and without del(17p), may be targetable by approved drugs, and further indicates the need for regular monitoring by sequencing to identify these patients.
{"title":"Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma","authors":"Dimitrios Tsallos, Nemo K. Ikonen, Juho J. Miettinen, Muntasir M. Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O'Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Caroline A. Heckman","doi":"10.1101/2024.08.23.24312359","DOIUrl":"https://doi.org/10.1101/2024.08.23.24312359","url":null,"abstract":"Despite development of several effective therapies for multiple myeloma (MM), the prognosis of patients with partial deletion of chromosome 17 (del(17p)) and <em>TP53</em> aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and transcriptome sequencing plus proteomics) and functional ex vivo drug screening to samples from 167 patients with MM, we uncovered novel therapeutic vulnerabilities specific to <em>TP53</em> mutated MM. Our findings revealed a distinct sensitivity profile to a range of inhibitors (mitotic, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR inhibitors) irrespective of 17p deletion status. Conversely, no increase in sensitivity was observed for monoallelic <em>TP53</em> (del(17p) with WT <em>TP53</em>) when compared to WT <em>TP53</em> samples, highlighting the remaining unmet clinical need. Notably, plicamycin, an RNA synthesis inhibitor linked to modulation of chromatin structure and increased transcription, emerged as particularly efficacious for <em>TP53</em> mutated MM. The increased sensitivity correlated with higher protein expression of the drug targets: HDAC2, HSP90AA1 and multiple ribosomal subunits. Additionally, we observed increased RNA expression of G2M checkpoint, E2F targets and mTORC1 signaling in our cohort and the MMRF-CoMMpass (NCT01454297) study in <em>TP53</em> mutated MM. Harmonization of multi-omics data with ex vivo drug screening results revealed that <em>TP53</em> mutated MM is functionally distinct from MM with monoallelic <em>TP53</em>, and demonstrate that MM with mutated <em>TP53</em>, with and without del(17p), may be targetable by approved drugs, and further indicates the need for regular monitoring by sequencing to identify these patients.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Sickle Cell Disease (SCD) affects over 100,000 individuals in the United States and 20 million globally, causing acute and chronic pain. The disease is characterized by misshapen red blood cells caused by mutations in beta-hemoglobin genes. SCD leads to multiorgan damage, chronic anemia, and severe pain crises, with a median life expectancy of 43 years. Current treatments involve opioids, blood transfusions, and hydroxyurea. Amino acids, especially L-Glutamine, have shown promise in managing SCD pain. This systematic review aims to comprehensively analyze the effects of amino acid treatments on vaso-occlusive pain crises in SCD patients. Methods: Following the Cochrane Handbook and PRISMA-P guidelines, this systematic review will include studies comparing amino acid treatment to placebo or standard care for SCD pain crises. Eligible studies of all age ranges, settings, and amino acid types will be considered. A comprehensive search strategy will be employed in PubMed, Embase, and Scopus databases. Studies will be assessed for risk of bias using Cochrane's RoB2 tool. Primary outcomes include a reduction in pain, measured quantitatively through pain scales. Secondary outcomes encompass quality of life, hospital length of stay, and opioid equivalents used. Discussion: Existing literature underscores the therapeutic potential of amino acids, yet there still lacks a systematic review comparing the overall effects of different amino acid treatments for vaso-occlusive crises in patients with SCD. This review aims to serve as a valuable resource for clinicians, offering insights into amino acid interventions as alternatives or supplements to opioid treatments. Additionally, it seeks to encourage further randomized clinical trials, contributing to an informed clinical use of amino acids for pain management in SCD. Ultimately, the findings aim to enhance the understanding of the therapeutic effects of essential amino acids on pediatric patients with SCD, facilitating evidence-based clinical decisions.
{"title":"Evaluating the Therapeutic Effects of Amino Acid Treatment on Vaso-Occlusive Pain in Sickle Cell Disease: A Systematic Review and Meta-Analysis Protocol","authors":"Bohan Zhang, Ciaran Bubb, Vivian Dong, Sophie Yao, Priyal Patel, Aanya Shahani, Katie Lobner, Oluwakemi Badaki-Makun","doi":"10.1101/2024.08.08.24311691","DOIUrl":"https://doi.org/10.1101/2024.08.08.24311691","url":null,"abstract":"Introduction: Sickle Cell Disease (SCD) affects over 100,000 individuals in the United States and 20 million globally, causing acute and chronic pain. The disease is characterized by misshapen red blood cells caused by mutations in beta-hemoglobin genes. SCD leads to multiorgan damage, chronic anemia, and severe pain crises, with a median life expectancy of 43 years. Current treatments involve opioids, blood transfusions, and hydroxyurea. Amino acids, especially L-Glutamine, have shown promise in managing SCD pain. This systematic review aims to comprehensively analyze the effects of amino acid treatments on vaso-occlusive pain crises in SCD patients.\u0000Methods: Following the Cochrane Handbook and PRISMA-P guidelines, this systematic review will include studies comparing amino acid treatment to placebo or standard care for SCD pain crises. Eligible studies of all age ranges, settings, and amino acid types will be considered. A comprehensive search strategy will be employed in PubMed, Embase, and Scopus databases. Studies will be assessed for risk of bias using Cochrane's RoB2 tool. Primary outcomes include a reduction in pain, measured quantitatively through pain scales. Secondary outcomes encompass quality of life, hospital length of stay, and opioid equivalents used.\u0000Discussion: Existing literature underscores the therapeutic potential of amino acids, yet there still lacks a systematic review comparing the overall effects of different amino acid treatments for vaso-occlusive crises in patients with SCD. This review aims to serve as a valuable resource for clinicians, offering insights into amino acid interventions as alternatives or supplements to opioid treatments. Additionally, it seeks to encourage further randomized clinical trials, contributing to an informed clinical use of amino acids for pain management in SCD. Ultimately, the findings aim to enhance the understanding of the therapeutic effects of essential amino acids on pediatric patients with SCD, facilitating evidence-based clinical decisions.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-23DOI: 10.1101/2024.07.19.24310679
Julie A.I. Thoms, Feng Yan, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Jesslyn Saw, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C. Nunez, Purvi M. Kakadia, Golam Sarower Bhuyan, Xiaoheng Zou, Mary Nguyen, Elaheh S. Ghodousi, Forrest C. Koch, Fatemeh Vafaee, Russell Pickford, Mark J. Raftery, Sally Hough, Griselda Buckland, Michelle Bailey, Yuvaraj Ghodke, Noorul Absar, Lachlin Vaughan, Leonardo Pasalic, Chun Y. Fong, Melita Kenealy, Devendra K. Hiwase, Rohanna I. Stoddart, Soma Mohammed, Linda Lee, Freda H. Passam, Stephen R. Larsen, Kevin J. Spring, Kristen K. Skarratt, Patricia Rebeiro, Peter Presgrave, William S. Stevenson, Silvia Ling, Campbell Tiley, Stephen J. Fuller, Fernando Roncolato, Anoop K. Enjeti, Dirk Hoenemann, Charlotte Lemech, Christopher J. Jolly, Stefan K. Bohlander, David J. Curtis, Jason W.H. Wong, Ashwin Unnikrishnan, Mark Hertzberg, Jake Olivier, Mark N. Polizzotto, John E. Pimanda
Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with in vivo dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.
{"title":"Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells in vivo","authors":"Julie A.I. Thoms, Feng Yan, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Jesslyn Saw, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C. Nunez, Purvi M. Kakadia, Golam Sarower Bhuyan, Xiaoheng Zou, Mary Nguyen, Elaheh S. Ghodousi, Forrest C. Koch, Fatemeh Vafaee, Russell Pickford, Mark J. Raftery, Sally Hough, Griselda Buckland, Michelle Bailey, Yuvaraj Ghodke, Noorul Absar, Lachlin Vaughan, Leonardo Pasalic, Chun Y. Fong, Melita Kenealy, Devendra K. Hiwase, Rohanna I. Stoddart, Soma Mohammed, Linda Lee, Freda H. Passam, Stephen R. Larsen, Kevin J. Spring, Kristen K. Skarratt, Patricia Rebeiro, Peter Presgrave, William S. Stevenson, Silvia Ling, Campbell Tiley, Stephen J. Fuller, Fernando Roncolato, Anoop K. Enjeti, Dirk Hoenemann, Charlotte Lemech, Christopher J. Jolly, Stefan K. Bohlander, David J. Curtis, Jason W.H. Wong, Ashwin Unnikrishnan, Mark Hertzberg, Jake Olivier, Mark N. Polizzotto, John E. Pimanda","doi":"10.1101/2024.07.19.24310679","DOIUrl":"https://doi.org/10.1101/2024.07.19.24310679","url":null,"abstract":"Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with in vivo dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141769372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.1101/2024.07.10.24310235
Felicia Cao, Yueling Xiu, Michael Mohnasky, Jonathan S Serody, Paul Armistead, Gianpietro Dotti, Melody Smith, Jonathan Huggins, Julia Messina, Bhanu Ramachandran, Jennifer Saullo, Joseph Stromberg, Manish K Saha, Megan Walsh, Barbara Savoldo, Natalie Grover, Heather I Henderson, Tessa M. Andermann
Infections are increasingly recognized as a common complication of chimeric antigen receptor (CAR) T-cell therapy. The incidence of clinically-defined infection after CD19.CAR T-cell therapy for relapsed/refractory lymphoma ranges from 60-90% in the first year after CAR T-cell therapy and is the most common cause for non-relapse mortality. However, infectious risk after CAR T-cell therapy targeting other malignancies is not well understood. Herein, we report for the first time, infectious complications after CD30.CAR T-cell treatment for patients with Hodgkin's lymphoma and peripheral T-cell lymphoma. Since CD30 is only expressed on a subset of activated T and B-cells, we hypothesized that CD30.CAR T-cell patients would have reduced incidence and severity of infections after infusion compared to CD19.CAR T-cell patients. We retrospectively evaluated all 64 patients who received CD30.CAR T-cells at a single institution between 2016-2021, and assessed infections within one year after cell infusion, comparing these data to a contemporary cohort of 50 patients who received CD19.CAR T-cells at the same institution between 2018-2021. 23 CD30.CAR T-cell patients (36%) and 18 CD19.CAR T-cell patients (36%) developed a microbiologically confirmed infection. Infection severity and bacterial infections were higher in the CD19.CAR T-cell group compared to CD30.CAR T-cell recipients who more commonly had grade 1 respiratory viral infections. Our data reflect expected outcomes for severity and infection type in CD19.CAR T-cell patients and provide a benchmark for comparison with the novel CD30.CAR T-cell product. Although our findings require replication in a larger cohort, they have implications for antimicrobial prophylaxis guidelines after CD30.CAR T-cell therapy.
越来越多的人认识到，感染是嵌合抗原受体（CAR）T细胞疗法的常见并发症。CD19.CAR T细胞治疗复发/难治性淋巴瘤后的第一年，临床定义的感染发生率为60%-90%，是非复发死亡的最常见原因。然而，针对其他恶性肿瘤的 CAR T 细胞疗法后的感染风险还不十分清楚。在此，我们首次报告了霍奇金淋巴瘤和外周T细胞淋巴瘤患者接受CD30.CAR T细胞治疗后的感染并发症。由于 CD30 只在活化的 T 细胞和 B 细胞的一个子集上表达，我们假设与 CD19.CAR T 细胞患者相比，CD30.CAR T 细胞患者输注后感染的发生率和严重程度会降低。我们回顾性评估了 2016-2021 年间在一家机构接受 CD30.CAR T 细胞治疗的所有 64 例患者，评估了细胞输注后一年内的感染情况，并将这些数据与 2018-2021 年间在同一机构接受 CD19.CAR T 细胞治疗的 50 例患者的当代队列进行了比较。23名CD30.CAR T细胞患者（36%）和18名CD19.CAR T细胞患者（36%）发生了经微生物证实的感染。与CD30.CAR T细胞受者相比，CD19.CAR T细胞组的感染严重程度和细菌感染更高，CD30.CAR T细胞受者更常见的是1级呼吸道病毒感染。我们的数据反映了 CD19.CAR T 细胞患者的严重程度和感染类型的预期结果，并为与新型 CD30.CAR T 细胞产品进行比较提供了基准。虽然我们的研究结果需要在更大的群体中进行复制，但它们对CD30.CAR T细胞治疗后的抗菌预防指南具有一定的指导意义。
{"title":"Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults","authors":"Felicia Cao, Yueling Xiu, Michael Mohnasky, Jonathan S Serody, Paul Armistead, Gianpietro Dotti, Melody Smith, Jonathan Huggins, Julia Messina, Bhanu Ramachandran, Jennifer Saullo, Joseph Stromberg, Manish K Saha, Megan Walsh, Barbara Savoldo, Natalie Grover, Heather I Henderson, Tessa M. Andermann","doi":"10.1101/2024.07.10.24310235","DOIUrl":"https://doi.org/10.1101/2024.07.10.24310235","url":null,"abstract":"Infections are increasingly recognized as a common complication of chimeric antigen receptor (CAR) T-cell therapy. The incidence of clinically-defined infection after CD19.CAR T-cell therapy for relapsed/refractory lymphoma ranges from 60-90% in the first year after CAR T-cell therapy and is the most common cause for non-relapse mortality. However, infectious risk after CAR T-cell therapy targeting other malignancies is not well understood. Herein, we report for the first time, infectious complications after CD30.CAR T-cell treatment for patients with Hodgkin's lymphoma and peripheral T-cell lymphoma. Since CD30 is only expressed on a subset of activated T and B-cells, we hypothesized that CD30.CAR T-cell patients would have reduced incidence and severity of infections after infusion compared to CD19.CAR T-cell patients. We retrospectively evaluated all 64 patients who received CD30.CAR T-cells at a single institution between 2016-2021, and assessed infections within one year after cell infusion, comparing these data to a contemporary cohort of 50 patients who received CD19.CAR T-cells at the same institution between 2018-2021. 23 CD30.CAR T-cell patients (36%) and 18 CD19.CAR T-cell patients (36%) developed a microbiologically confirmed infection. Infection severity and bacterial infections were higher in the CD19.CAR T-cell group compared to CD30.CAR T-cell recipients who more commonly had grade 1 respiratory viral infections. Our data reflect expected outcomes for severity and infection type in CD19.CAR T-cell patients and provide a benchmark for comparison with the novel CD30.CAR T-cell product. Although our findings require replication in a larger cohort, they have implications for antimicrobial prophylaxis guidelines after CD30.CAR T-cell therapy.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-10DOI: 10.1101/2024.07.08.24310018
Laura Arthur, Nitin Mahajan, Jayakumar Vadakekolathu, Tom Leedom, David J Boocock, Clare Coveney, Alex Hamil, Kristann Magee, John Dean, Elizabeth Schramm, Benjamin Capoccia, Vincent Petit, Nupur Bhatnagar, Christian Pinset, Aways Younis, Craig Doig, Benjamin Thomas, Evangelia Williams, Lena Luukkonen, Yanira Ruiz-Heredia, Alejandro Martin Munoz, Paola Comune Pennacchi, Daniel Primo, Neysa Dagostino, Stacy K Lewis, Natasha Edwin, John Muth, Melissa Berrien-Elliott, Todd A Fehniger, Jan K Davidson-Moncada, Sergio Rutella
Background Natural killer (NK) cells originate from bone marrow precursors and mediate effective anti-tumor responses. Clinical trials of cytokine-primed memory-like (ML) NK cells in acute myeloid leukemia (AML) have demonstrated activity without major toxicity, including graft-versus-host disease or cytokine release syndrome. However, broad application of non-expanded, non-engineered ML NK cells has been hindered by limited availability of NK cells from a single donor, thereby precluding aggressive dose escalation and repeat dosing. W-NK1 is derived from human peripheral blood mononuclear cells undergoing ML reprogramming with a proprietary heteromeric fusion protein complex including IL-12, IL-15 and IL-18. Methods We conducted a multi-omics characterization of W-NK1 by interrogating its transcriptomic, proteomic and metabolic profile. Using functional assays, we assessed W-NK1s cytotoxicity under adverse culture conditions, as well as W-NK1s trafficking and killing abilities in immunodeficient mice engrafted with THP-1 AML. Finally, we evaluated W-NK1s phenotype and in vivo expansion kinetics in one patient with AML enrolled in study NCT05470140. Results W-NK1 displayed an activated, hyper-metabolic, and proliferative state differing from unstimulated conventional NK cells (cNK) from healthy donors. When compared to external single-cell NK datasets, W-NK1 was largely annotated as NKG2A+ and showed low relatedness with adaptive NK states characterized by HCMV-induced inflammatory memory. W-NK1 outperformed cNK cells in terms of in vitro killing of a broad panel of AML cell lines, with no appreciable cytotoxicity against normal cell lines. The expression of nutrient transporters was higher in W-NK1 compared to cNK cells and was retained even in adverse culture conditions designed to mimic an immunosuppressive tumor microenvironment. In mice engrafted with THP-1 AML, W-NK1 trafficked and efficiently homed to the bone marrow, where it mediated better tumor control than cNK cells. W-NK1 expanded, underwent phenotypic changes and persisted with effective elimination of circulating AML blasts through day 14 after infusion in one patient treated on clinical trial NCT05470140. Immunofluorescence staining of BM sections collected on day 28 showed increased expression of both CD56 and CD3 compared to a pre-treatment biopsy. Conclusions Our study offers a comprehensive characterization of W-NK1 as an effective cell therapy product for AML and solid tumor malignancies.
背景 自然杀伤（NK）细胞起源于骨髓前体，可介导有效的抗肿瘤反应。细胞因子激发的记忆样（ML）NK细胞在急性髓性白血病（AML）中的临床试验表明，这种细胞具有活性，且无重大毒性，包括移植物抗宿主病或细胞因子释放综合征。然而，非扩增、非工程ML NK细胞的广泛应用一直受到来自单一供体的NK细胞有限性的阻碍，从而无法进行积极的剂量升级和重复给药。W-NK1来源于人类外周血单核细胞，这些细胞在使用包括IL-12、IL-15和IL-18在内的专有异构体融合蛋白复合物进行ML重编程后获得。通过功能测试，我们评估了 W-NK1 在不利培养条件下的细胞毒性，以及 W-NK1 在移植有 THP-1 AML 的免疫缺陷小鼠体内的贩运和杀伤能力。最后，我们在 NCT05470140 研究中登记的一名 AML 患者体内评估了 W-NK1 的表型和体内扩增动力学。与外部单细胞 NK 数据集相比，W-NK1 大部分被注释为 NKG2A+，与以 HCMV 诱导的炎症记忆为特征的适应性 NK 状态的相关性较低。在体外杀伤多种急性髓细胞系方面，W-NK1 的表现优于 cNK 细胞，但对正常细胞系没有明显的细胞毒性。与 cNK 细胞相比，W-NK1 细胞中营养转运体的表达量更高，即使在模拟免疫抑制肿瘤微环境的不利培养条件下也能保持这种表达量。在移植了 THP-1 AML 的小鼠体内，W-NK1 向骨髓迁移并有效归巢，在骨髓中，它比 cNK 细胞能更好地控制肿瘤。在 NCT05470140 临床试验中，一名患者在输注 W-NK1 细胞后第 14 天，W-NK1 细胞扩增、发生表型变化并持续有效地消除了循环中的急性髓细胞白细胞。第 28 天收集的骨髓切片免疫荧光染色显示，与治疗前的活检相比，CD56 和 CD3 的表达均有所增加。
{"title":"An integrated multi-omics investigation of W-NK1, a cytokine-primed non-engineered natural killer cell therapy product","authors":"Laura Arthur, Nitin Mahajan, Jayakumar Vadakekolathu, Tom Leedom, David J Boocock, Clare Coveney, Alex Hamil, Kristann Magee, John Dean, Elizabeth Schramm, Benjamin Capoccia, Vincent Petit, Nupur Bhatnagar, Christian Pinset, Aways Younis, Craig Doig, Benjamin Thomas, Evangelia Williams, Lena Luukkonen, Yanira Ruiz-Heredia, Alejandro Martin Munoz, Paola Comune Pennacchi, Daniel Primo, Neysa Dagostino, Stacy K Lewis, Natasha Edwin, John Muth, Melissa Berrien-Elliott, Todd A Fehniger, Jan K Davidson-Moncada, Sergio Rutella","doi":"10.1101/2024.07.08.24310018","DOIUrl":"https://doi.org/10.1101/2024.07.08.24310018","url":null,"abstract":"Background Natural killer (NK) cells originate from bone marrow precursors and mediate effective anti-tumor responses. Clinical trials of cytokine-primed memory-like (ML) NK cells in acute myeloid leukemia (AML) have demonstrated activity without major toxicity, including graft-versus-host disease or cytokine release syndrome. However, broad application of non-expanded, non-engineered ML NK cells has been hindered by limited availability of NK cells from a single donor, thereby precluding aggressive dose escalation and repeat dosing. W-NK1 is derived from human peripheral blood mononuclear cells undergoing ML reprogramming with a proprietary heteromeric fusion protein complex including IL-12, IL-15 and IL-18.\u0000Methods We conducted a multi-omics characterization of W-NK1 by interrogating its transcriptomic, proteomic and metabolic profile. Using functional assays, we assessed W-NK1s cytotoxicity under adverse culture conditions, as well as W-NK1s trafficking and killing abilities in immunodeficient mice engrafted with THP-1 AML. Finally, we evaluated W-NK1s phenotype and in vivo expansion kinetics in one patient with AML enrolled in study NCT05470140.\u0000Results W-NK1 displayed an activated, hyper-metabolic, and proliferative state differing from unstimulated conventional NK cells (cNK) from healthy donors. When compared to external single-cell NK datasets, W-NK1 was largely annotated as NKG2A+ and showed low relatedness with adaptive NK states characterized by HCMV-induced inflammatory memory. W-NK1 outperformed cNK cells in terms of in vitro killing of a broad panel of AML cell lines, with no appreciable cytotoxicity against normal cell lines. The expression of nutrient transporters was higher in W-NK1 compared to cNK cells and was retained even in adverse culture conditions designed to mimic an immunosuppressive tumor microenvironment. In mice engrafted with THP-1 AML, W-NK1 trafficked and efficiently homed to the bone marrow, where it mediated better tumor control than cNK cells. W-NK1 expanded, underwent phenotypic changes and persisted with effective elimination of circulating AML blasts through day 14 after infusion in one patient treated on clinical trial NCT05470140. Immunofluorescence staining of BM sections collected on day 28 showed increased expression of both CD56 and CD3 compared to a pre-treatment biopsy.\u0000Conclusions Our study offers a comprehensive characterization of W-NK1 as an effective cell therapy product for AML and solid tumor malignancies.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-27DOI: 10.1101/2024.06.26.24309451
Sidheshwar Vishnu Bhendekar, Jay Kirtani, Rahul Naithani
Background: There is lack of data from India on prevalence of anemia of chronic disease or inflammation (ACD). Patients & methods: This was a prospective observational cross sectional prevalence study. Anemic patients underwent a complete blood count with peripheral smear, serum ferritin level, iron, total iron binding capacity, transferrin saturation, vitamin B12 and folic acid level, reticulocyte count and stool for occult blood. Other investigations were performed as required according to patients clinical profile. Results: Three hundred fifty five patients were enrolled. A total of 109 patients (30.7%) had anemia of chronic disease ACD (30.7%). Sixty three/263 (24%) females had ACD compared to 46/95 (48.4%) males. ACD was four times more common in age group 80 years and above (56.5%) compared to age group 18 to 39 years (13.9%). Seventy two (66%) patients had mild anemia, 19 patients (17%) had moderate anemia and 18 patients (16%) had severe anemia. Diabetes mellitus (44%), hypertension (39%) and chronic kidney disease (25%) were the commonest underlying morbidity. Thirty six patients (33%) had no underlying comorbidity or cause. Conclusion: The prevalence of anemia of chronic disease increases with age. Majority of anemia of chronic disease patients have mild anemia.
{"title":"Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India","authors":"Sidheshwar Vishnu Bhendekar, Jay Kirtani, Rahul Naithani","doi":"10.1101/2024.06.26.24309451","DOIUrl":"https://doi.org/10.1101/2024.06.26.24309451","url":null,"abstract":"Background: There is lack of data from India on prevalence of anemia of chronic disease or inflammation (ACD). Patients & methods: This was a prospective observational cross sectional prevalence study. Anemic patients underwent a complete blood count with peripheral smear, serum ferritin level, iron, total iron binding capacity, transferrin saturation, vitamin B12 and folic acid level, reticulocyte count and stool for occult blood. Other investigations were performed as required according to patients clinical profile. Results: Three hundred fifty five patients were enrolled. A total of 109 patients (30.7%) had anemia of chronic disease ACD (30.7%). Sixty three/263 (24%) females had ACD compared to 46/95 (48.4%) males. ACD was four times more common in age group 80 years and above (56.5%) compared to age group 18 to 39 years (13.9%). Seventy two (66%) patients had mild anemia, 19 patients (17%) had moderate anemia and 18 patients (16%) had severe anemia. Diabetes mellitus (44%), hypertension (39%) and chronic kidney disease (25%) were the commonest underlying morbidity. Thirty six patients (33%) had no underlying comorbidity or cause. Conclusion: The prevalence of anemia of chronic disease increases with age. Majority of anemia of chronic disease patients have mild anemia.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-23DOI: 10.1101/2024.06.22.24309250
Kane A Foster, Elise Rees, Louise Ainley, Eileen M Boyle, Lydia Lee, Gwennan Ward, Daria Galas-Filipowicz, Anna Mikolajczak, Emma J Lyon, Dylan Jankovic, Jasmine Rahman, Mahima Turakhia, Imran Uddin, Gordon Beattie, Yvette Hoade, Catherine Zhu, James L Reading, Ieuan G Walker, Michael A Chapman, Karthik Ramasamy, Javier Herrero, Benny Chain, Sergio A Quezada, Kwee Yong
The haematological malignancy multiple myeloma is associated with skewed T-cell activation and function. T-cell alterations are detectable in asymptomatic myeloma precursor conditions and have the potential to identify precursor patients at imminent risk of progression. However, what myeloma-associated T-cells alterations represent mechanistically, how they relate to tumour burden and gene expression, and what influences high inter-patient variability in immune composition remains unknown. Here, we assembled the largest ever dataset of published and newly-generated single-cell RNA and TCR sequencing of the marrow and blood from patients with myeloma, precursor conditions, and age-matched non-cancer controls. We show myeloma is not associated with T-cell exhaustion and instead defined by a pattern of T-cell differentiation resembling antigen-driven terminal memory differentiation. Myeloma-associated T-cell differentiation was dependent on tumour-intrinsic features including tumour burden and tumour expression of antigen-presentation genes. Expanded TCR clones accumulating in myeloma were not enriched for viral specificity and were detected in effector states in highly infiltrated marrows. Together, these results suggest anti-tumour immunity drives a novel form of cancer-associated T-cell memory differentiation in myeloma.
血液恶性肿瘤多发性骨髓瘤与 T 细胞活化和功能失调有关。在无症状的骨髓瘤前驱体中可检测到 T 细胞的改变，并有可能识别出面临迫在眉睫的恶化风险的前驱体患者。然而，骨髓瘤相关 T 细胞的改变在机理上代表什么，它们与肿瘤负荷和基因表达的关系如何，以及是什么影响了患者间免疫组成的高变异性，这些仍是未知数。在这里，我们对骨髓瘤患者的骨髓和血液、前驱症状以及年龄匹配的非癌症对照组的已发表和新产生的单细胞 RNA 和 TCR 测序数据集进行了汇总，这是迄今为止最大的数据集。我们发现骨髓瘤与 T 细胞衰竭无关，而是由一种类似于抗原驱动的终末记忆分化的 T 细胞分化模式定义的。骨髓瘤相关的T细胞分化取决于肿瘤内在特征，包括肿瘤负荷和肿瘤中抗原递呈基因的表达。骨髓瘤中积累的扩大的TCR克隆并不富含病毒特异性，而且在高度浸润的骨髓中以效应状态被检测到。总之，这些结果表明，抗肿瘤免疫推动了骨髓瘤中一种新型的癌症相关 T 细胞记忆分化。
{"title":"Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution","authors":"Kane A Foster, Elise Rees, Louise Ainley, Eileen M Boyle, Lydia Lee, Gwennan Ward, Daria Galas-Filipowicz, Anna Mikolajczak, Emma J Lyon, Dylan Jankovic, Jasmine Rahman, Mahima Turakhia, Imran Uddin, Gordon Beattie, Yvette Hoade, Catherine Zhu, James L Reading, Ieuan G Walker, Michael A Chapman, Karthik Ramasamy, Javier Herrero, Benny Chain, Sergio A Quezada, Kwee Yong","doi":"10.1101/2024.06.22.24309250","DOIUrl":"https://doi.org/10.1101/2024.06.22.24309250","url":null,"abstract":"The haematological malignancy multiple myeloma is associated with skewed T-cell activation and function. T-cell alterations are detectable in asymptomatic myeloma precursor conditions and have the potential to identify precursor patients at imminent risk of progression. However, what myeloma-associated T-cells alterations represent mechanistically, how they relate to tumour burden and gene expression, and what influences high inter-patient variability in immune composition remains unknown. Here, we assembled the largest ever dataset of published and newly-generated single-cell RNA and TCR sequencing of the marrow and blood from patients with myeloma, precursor conditions, and age-matched non-cancer controls. We show myeloma is not associated with T-cell exhaustion and instead defined by a pattern of T-cell differentiation resembling antigen-driven terminal memory differentiation. Myeloma-associated T-cell differentiation was dependent on tumour-intrinsic features including tumour burden and tumour expression of antigen-presentation genes. Expanded TCR clones accumulating in myeloma were not enriched for viral specificity and were detected in effector states in highly infiltrated marrows. Together, these results suggest anti-tumour immunity drives a novel form of cancer-associated T-cell memory differentiation in myeloma.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-28DOI: 10.1101/2024.05.28.24308028
Patience Kuona, Gwendoline Q Kandawasvika, Catherine Chunda-Liyoka, Ian M Ruredzo, Pauline M Sambo, Pamela Gorejena-Chidawanyika, Hamakwa M Mantina, Takudzwa J Mtisi, Cynthia Phiri, Lawson Chikara, Natasha M Kaweme, Exavior Chivige, Jombo Namushi, Tendai Maborekeke, Uma H Uthale, Collen Masimirembwa
Of the 500 000 children born with sickle cell disease annually, most cases occur in Africa, contributing to significant morbidity and mortality associated with limited sickle cell disease (SCD) health outcomes data and reduced access to therapeutic plus preventive care. We aim to develop and manage a standardized electronic SCD registry, establish consistent standards of care (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia. This five-year program employs mixed methods that include infrastructure and skilled manpower capacity building of SCD clinics, registry, biobanking, cohort and implementation science research studies to improve SCD treatment outcomes. We are collaborating with the SickleInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the African Institute of Biomedical Sciences and Technology (AiBST) and St Jude’s Children Research Hospital. We established the SCD registry in Zimbabwe and Zambia for children and adult patients enrolling 1796/4000 (45%) participants to date. We are participating in SickleInAfrica consortium research activities, training health workers and educating SCD patient communities on SoC. This collaboration with African researchers, policymakers, health workers, and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.
{"title":"Sickle hemoglobinopathy research in Zimbabwe and Zambia (SHAZ): Protocol for setting up an international Sickle Cell Disease registry","authors":"Patience Kuona, Gwendoline Q Kandawasvika, Catherine Chunda-Liyoka, Ian M Ruredzo, Pauline M Sambo, Pamela Gorejena-Chidawanyika, Hamakwa M Mantina, Takudzwa J Mtisi, Cynthia Phiri, Lawson Chikara, Natasha M Kaweme, Exavior Chivige, Jombo Namushi, Tendai Maborekeke, Uma H Uthale, Collen Masimirembwa","doi":"10.1101/2024.05.28.24308028","DOIUrl":"https://doi.org/10.1101/2024.05.28.24308028","url":null,"abstract":"Of the 500 000 children born with sickle cell disease annually, most cases occur in Africa, contributing to significant morbidity and mortality associated with limited sickle cell disease (SCD) health outcomes data and reduced access to therapeutic plus preventive care. We aim to develop and manage a standardized electronic SCD registry, establish consistent standards of care (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia. This five-year program employs mixed methods that include infrastructure and skilled manpower capacity building of SCD clinics, registry, biobanking, cohort and implementation science research studies to improve SCD treatment outcomes. We are collaborating with the SickleInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the African Institute of Biomedical Sciences and Technology (AiBST) and St Jude’s Children Research Hospital. We established the SCD registry in Zimbabwe and Zambia for children and adult patients enrolling 1796/4000 (45%) participants to date. We are participating in SickleInAfrica consortium research activities, training health workers and educating SCD patient communities on SoC. This collaboration with African researchers, policymakers, health workers, and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141188048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：